MAX SENNA MANO
Projetos de Pesquisa
Unidades Organizacionais
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
- Patterns of post-operative radiotherapy in breast cancer patients after neoadjuvant chemotherapy(2017) LOPES, K. M.; FREITAS, T. B. De; CARVALHO, H. A.; PEREIRA, A. A.; SILVA, S. B.; STUART, S. R.; MANO, M. S.; FILASSI, J. R.; MARTA, G. N.
bookPart Carcinoma de Mama: Terapia Endócrina Neoadjuvante(2017) MANO, Max; LINCK, Rudinei Diogo Marques- Impact of radiation therapy delay in patients underwent neoadjuvant chemotherapy and breast surgery(2017) SILVA, S.; PEREIRA, A.; KENNYA, M.; GUSTAVO, M.; MANO, M.
- Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy(2017) MARTA, Gustavo Nader; POORTMANS, Philip; BARROS, Alfredo C. de; FILASSI, Jose Roberto; FREITAS JUNIOR, Ruffo; AUDISIO, Riccardo A.; MANO, Max Senna; METERISSIAN, Sarkis; DESNYDER, Sarah M.; BUCHHOLZ, Thomas A.; HIJAL, TarekPurpose/Objective(s): Skin sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) have entered routine surgical practice for breast cancer, though their oncologic safety has not been established in randomized controlled trials. The aim of this study was to evaluate and compare radiation oncologists' and breast surgeons' opinions concerning the indications of post-operative radiation therapy (PORT) after SSM and NSM. Materials/Methods: Radiation oncologists and breast surgeons from North America, South America and Europe were invited to contribute in this study. A 22-question survey was used to evaluate their opinions. Results: A total of 550 physicians (298 radiation oncologists and 252 breast surgeons) answered the survey. The majority of responders affirmed that PORT should be performed in early-stage (stages I and II) breast cancer for patients who present with risk factors for relapse after SSM and NSM. They considered age, lymph node involvement, tumor size, extracapsular extension, involved surgical margins, lymphovascular invasion, triple negative receptor status and multicentric presentation as major risk factors. Considering that after SSM and NSM, residual breast tissue can be left behind, the residual tissue considered as acceptable in the context of an oncologic surgery were 1-5 mm for breast surgeons. There is no consensus for the necessity of evaluating residual breast tissue through breast imaging. Conclusion: Although the indications of PORT after SSM and NSM vary among practitioners, standard risk factors for relapse are considered as important by radiation oncologists and breast surgeons.
- Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region(2017) MARTINEZ-MESA, J.; WERUTSKY, G.; MICHIELS, S.; PEREIRA FILHO, C. A. S.; DUENAS-GONZALEZ, A.; ZARBA, J. J.; MANO, M.; VILLARREAL-GARZA, C.; GOMEZ, H.; BARRIOS, C. H.Objective: To evaluate whether a country's Human Development Index (HDI) can help explain the differences in the country's breast cancer and gynecological cancer incidence and mortality rates in the Pan-American region. Study design: Ecological analysis. Methods: Pan-American region countries with publicly available data both in GLOBOCAN 2012 and the United Nations Development Report 2012 were included (n = 28). Incidence and mortality rates age-standardized per 100,000 were natural log-transformed for breast cancer, ovarian cancer, corpus uteri cancer, and cervical cancer. The mortality-to-incidence ratio (MIR) was calculated for each site. Pearson's correlation test and a simple linear regression were performed. Results: The HDI showed a positive correlation with breast cancer and ovarian cancer incidence and mortality rates, respectively, and a negative correlation with cervical cancer incidence and mortality rates. The HDI and corpus uteri cancer showed no association. MIR and the HDI showed a negative correlation for all tumor types except ovarian cancer. An increment in 1 HDI unit leads to changes in cancer rates: in breast cancer incidence beta = 4.03 (95% confidence interval [CI] 2.61; 5.45) P < 0.001, breast cancer mortality beta = 1.76 (95% CI 0.32; 3.21) P = 0.019, and breast cancer-MIR beta = -0.705 (95% CI 0.704; 0.706) P < 0.001; in cervical cancer incidence beta = -3.28 (95% CI -4.78; -1.78) P < 0.001, cervical cancer mortality beta = -4.63 (95% CI -6.10; -3.17) P < 0.001, and cervical cancer-MIR beta = -1.35 (95% CI -1.83; -0.87) P < 0.001; in ovarian cancer incidence beta = 3.26 (95% CI 1.78; 4.75) P < 0.001, ovarian cancer mortality beta = 1.82 (95% CI.0.44; 3.20) P = 0.012, and ovarian cancer-MIR beta = 5.10 (95% CI 3.22; 6.97) P < 0.001; in corpus uteri cancer incidence beta = 2.37 (95% CI -0.33; 5.06) P = 0.83, corpus uteri cancer mortality beta = 0.68 (95% CI -2.68; 2.82) P = 0.96, and corpus uteri cancer-MIR beta = -2.30 (95% CI -3.19; -1.40) P < 0.001. Conclusions: A country's HDI should be considered to understand disparities in breast cancer and gynecological cancer in the Pan-American region.
- Do socioeconomic status and comorbidity affect survival in women with breast cancer living in the city of Sao Paulo, Brazil?(2017) RIBEIRO, Karina Braga; ANDRADE, Felipe; ANDRADE, Danubia; PEDRO, Sibelle; YOSHIMURA, Adriana; GERONYMO, Beatriz; ANDRADE, Juliana; GONCALVES, Marina Sahade; TESTA, Laura; LINCK, Rudinei Diogo Marques; HANNA, Samir Abdallah; MANO, Max S.; SAMPAIO, Marcelo; BARROS, Alfredo C. S. D. de
- Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study(2017) BARRIOS, C. H.; UEMA, D.; CRONENBERGER, E.; LIMA, V.; BINES, J.; SANT'ANA, R. O. de; BATISTA, M. L.; DYBAL, V.; LIEDKE, P.; BEATO, C.; NERON, Y. V.; GIACOMAZZI, J.; SANTOS, L. dos; ISMAEL, G.; AZAMBUJA, A.; ANDRADE, D.; ROSA, D. D.; BORGES, G.; MANO, M.; MARTINEZ-MESA, J.; ZAFFARONI, F.; WERUTSKY, G.
- Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America(2017) LANDEIRO, L. G.; FRAILE, N. M. P.; FEDE, A. B.; FONSECA, L. G.; TESTA, L.; PETRY, V.; GONCALVES, M. S.; COSTA, R. D. P.; COHN, D. B.; FERRARI, M. M.; SUNAHARA, R. S.; GOUVEIA, A. C. C. de; MANO, M. S.